{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:40:31Z","timestamp":1777052431407,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polygenic risk scores (PRSs) strongly discriminate for prostate cancer risk at the population level. The role of these genetic scores in determining prostate cancer survival is unclear, potentially due to methodological issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 19,607 men from the Malm\u00f6 Diet and Cancer Study (MDCS) and the Health Professionals Follow-up Study (HPFS) and analyzed 20-year incidence and mortality (from full cohort analyses) and survival (from case-only analyses) according to a 451-variant PRS. For most of the men included, early access to prostate-specific antigen (PSA) testing was limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In full cohort analyses, a PRS at or above the median (vs. below the median) shows a strong association with prostate cancer incidence (hazard ratio (HR) 3.02, 95% CI 2.78-3.28) and, somewhat stronger, with prostate cancer mortality (HR 3.26, 95% CI 2.63-4.04). As expected, case-only survival analyses of prostate cancer death show a similar direction (HR 1.21, 95% CI 0.98-1.50), which becomes stronger when excluding variants linked to PSA (HR 1.25, 95% CI, 1.01-1.54), in particular in the age group 65-74 years at diagnosis (HR 1.72, 95% CI 1.21-2.45). In the other age groups, HRs are close to or below 1. This indicates that standard case-only survival estimates may not accurately reflect risk across age, consistent with age-dependent selection mechanisms, and further points to an influence from disease detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, these findings support that inherited genetic risk captured by the 451-variant PRS may have an influence on prostate cancer survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01603-9","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:26:28Z","timestamp":1777044388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polygenic risk score and 20-year prostate cancer-specific mortality and survival"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-4744","authenticated-orcid":false,"given":"Anna","family":"Plym","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-1311","authenticated-orcid":false,"given":"Konrad H.","family":"Stopsack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris","family":"Baras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Regeneron Genetics Center","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-6310","authenticated-orcid":false,"given":"Isabel","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clements","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn L.","family":"Penney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-0219","authenticated-orcid":false,"given":"Edward","family":"Giovannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorelei A.","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-0544","authenticated-orcid":false,"given":"Fredrik","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","volume":"23","author":"JB Hjelmborg","year":"2014","unstructured":"Hjelmborg, J. B. et al. The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol. Biomark. Prev. 23, 2303\u20132310 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren, O. et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur. Urol. 84, 191\u2013206 (2023).","journal-title":"Eur. Urol."},{"key":"1603_CR3","unstructured":"Wang, A. et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat. Genet. (2023)."},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jnci\/djac199","volume":"115","author":"MS Pagadala","year":"2023","unstructured":"Pagadala, M. S. et al. Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. J. Natl. Cancer Inst. 115, 190\u2013199 (2023).","journal-title":"J. Natl. Cancer Inst."},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1158\/1078-0432.CCR-22-1723","volume":"28","author":"A Plym","year":"2022","unstructured":"Plym, A. et al. Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years. Clin. Cancer Res. 28, 4926\u20134933 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/ijc.30931","volume":"141","author":"EM Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano, E. M. et al. Methodological considerations for disentangling a risk factor\u2019s influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women\u2019s Health Initiative. Int J. Cancer 141, 2281\u20132290 (2017).","journal-title":"Int J. Cancer"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2022.12.021","volume":"83","author":"TM Seibert","year":"2023","unstructured":"Seibert, T. M. et al. Genetic risk prediction for prostate cancer: implications for early detection and prevention. Eur. Urol. 83, 241\u2013248 (2023).","journal-title":"Eur. Urol."},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41391-017-0029-2","volume":"21","author":"LM FitzGerald","year":"2018","unstructured":"FitzGerald, L. M. et al. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 21, 228\u2013237 (2018).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.eururo.2018.06.021","volume":"74","author":"W Li","year":"2018","unstructured":"Li, W. et al. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur. Urol. 74, 710\u2013719 (2018).","journal-title":"Eur. Urol."},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","volume":"53","author":"DV Conti","year":"2021","unstructured":"Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat. Genet 53, 65\u201375 (2021).","journal-title":"Nat. Genet"},{"key":"1603_CR11","doi-asserted-by":"crossref","unstructured":"Rumpf, F. et al. Impact of family history and germline genetic risk single nucleotide polymorphisms on long-term outcomes of favorable-risk prostate cancer. J. Urol. 2024:101097JU0000000000003927.","DOI":"10.1097\/JU.0000000000003927"},{"key":"1603_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ypmed.2014.02.003","volume":"62","author":"HR Banack","year":"2014","unstructured":"Banack, H. R. & Kaufman, J. S. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev. Med. 62, 96\u2013102 (2014).","journal-title":"Prev. Med"},{"key":"1603_CR13","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1097\/EDE.0000000000000653","volume":"28","author":"MJ Stensrud","year":"2017","unstructured":"Stensrud, M. J., Valberg, M. & Aalen, O. O. Can Collider Bias Explain Paradoxical Associations? Epidemiology 28, e39\u2013e40 (2017).","journal-title":"Epidemiology"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2796.1993.tb00647.x","volume":"233","author":"G Berglund","year":"1993","unstructured":"Berglund, G., Elmstahl, S., Janzon, L. & Larsson, S. A. The Malmo Diet and Cancer Study. Design and feasibility. J. Intern. Med. 233, 45\u201351 (1993).","journal-title":"J. Intern. Med."},{"key":"1603_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2017.10.004","volume":"73","author":"M Assel","year":"2018","unstructured":"Assel, M. et al. Association between lead time and prostate cancer grade: evidence of grade progression from long-term follow-up of large population-based cohorts not subject to prostate-specific antigen screening. Eur. Urol. 73, 961\u2013967 (2018).","journal-title":"Eur. Urol."},{"key":"1603_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/0140-6736(91)90542-W","volume":"338","author":"EB Rimm","year":"1991","unstructured":"Rimm, E. B. et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 338, 464\u2013468 (1991).","journal-title":"Lancet"},{"key":"1603_CR17","doi-asserted-by":"publisher","first-page":"e0173997","DOI":"10.1371\/journal.pone.0173997","volume":"12","author":"S Lindstrom","year":"2017","unstructured":"Lindstrom, S. et al. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS ONE 12, e0173997 (2017).","journal-title":"PLoS ONE"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2022.05.008","volume":"83","author":"A Plym","year":"2023","unstructured":"Plym, A. et al. A healthy lifestyle in men at increased genetic risk for prostate cancer. Eur. Urol. 83, 343\u2013351 (2023).","journal-title":"Eur. Urol."},{"key":"1603_CR19","doi-asserted-by":"publisher","first-page":"e2420034","DOI":"10.1001\/jamanetworkopen.2024.20034","volume":"7","author":"A Plym","year":"2024","unstructured":"Plym, A. et al. Early prostate cancer deaths among men with higher vs lower genetic risk. JAMA Netw. Open 7, e2420034 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i04","volume":"38","author":"A Allignol","year":"2011","unstructured":"Allignol, A., Schumacher, M. & Beyersmann, J. Empirical transition matrix of multi-state models: the etm Package. J. Stat. Softw. 38, 1\u201315 (2011).","journal-title":"J. Stat. Softw."},{"key":"1603_CR21","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/JCO.22.01978","volume":"41","author":"Lopes Cardozo","year":"2023","unstructured":"Lopes Cardozo et al. Associations of a breast cancer polygenic risk score with tumor characteristics and survival. J. Clin. Oncol. 41, 1849\u20131863 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1603_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104454","volume":"89","author":"J Xin","year":"2023","unstructured":"Xin, J. et al. Prognostic evaluation of polygenic risk score underlying pan-cancer analysis: evidence from two large-scale cohorts. EBioMedicine 89, 104454 (2023).","journal-title":"EBioMedicine"},{"key":"1603_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/ije\/dyx206","volume":"47","author":"MR Munaf\u00f2","year":"2018","unstructured":"Munaf\u00f2, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. Int J. Epidemiol. 47, 226\u2013235 (2018).","journal-title":"Int J. Epidemiol."},{"key":"1603_CR24","first-page":"1018","volume":"26","author":"H Yaghootkar","year":"2017","unstructured":"Yaghootkar, H. et al. Quantifying the extent to which index event biases influence large genetic association studies. Hum. Mol. Genet. 26, 1018\u20131030 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"1603_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/EDE.0000000000000621","volume":"28","author":"MJ Stensrud","year":"2017","unstructured":"Stensrud, M. J., Valberg, M., R\u00f8ysland, K. & Aalen, O. O. Exploring selection bias by causal frailty models: the magnitude matters. Epidemiology 28, 379\u2013386 (2017).","journal-title":"Epidemiology"},{"key":"1603_CR26","doi-asserted-by":"crossref","unstructured":"Zhang Z, et al. Identifying patients at risk of early lethal prostate cancer by integrating family history, polygenic risk score, rare variants in dna repair genes, and lifestyle factors. Eur Urol Oncol. (2025).","DOI":"10.1016\/j.euo.2025.03.008"},{"key":"1603_CR27","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/EDE.0000000000000131","volume":"25","author":"WD Flanders","year":"2014","unstructured":"Flanders, W. D., Eldridge, R. C. & McClellan, W. A nearly unavoidable mechanism for collider bias with index-event studies. Epidemiology 25, 762\u2013764 (2014).","journal-title":"Epidemiology"},{"key":"1603_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.amjmed.2014.10.043","volume":"128","author":"M Lajous","year":"2015","unstructured":"Lajous, M., Banack, H. R., Kaufman, J. S. & Hern\u00e1n, M. A. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. Am. J. Med. 128, 334\u2013336 (2015).","journal-title":"Am. J. Med."},{"key":"1603_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01015-w","volume":"20","author":"J Bj\u00f6rk","year":"2020","unstructured":"Bj\u00f6rk, J., Nilsson, A., Bonander, C. & Str\u00f6mberg, U. A novel framework for classification of selection processes in epidemiological research. BMC Med. Res. Methodol. 20, 155 (2020).","journal-title":"BMC Med. Res. Methodol."},{"key":"1603_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10985-015-9335-y","volume":"21","author":"OO Aalen","year":"2015","unstructured":"Aalen, O. O., Cook, R. J. & R\u00f8ysland, K. Does Cox analysis of a randomized survival study yield a causal treatment effect? Lifetime data Anal. 21, 579\u2013593 (2015).","journal-title":"Lifetime data Anal."},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/aje\/kwx077","volume":"185","author":"MA Hern\u00e1n","year":"2017","unstructured":"Hern\u00e1n, M. A. Invited commentary: selection bias without colliders. Am. J. Epidemiol. 185, 1048\u20131050 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"1603_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19478-2","volume":"11","author":"GJ Griffith","year":"2020","unstructured":"Griffith, G. J. et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat. Commun. 11, 5749 (2020).","journal-title":"Nat. Commun."},{"key":"1603_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1055-9965.EPI-16-0559","volume":"26","author":"ER Mayeda","year":"2017","unstructured":"Mayeda, E. R. & Glymour, M. M. The obesity paradox in survival after cancer diagnosis: tools for evaluation of potential bias. Cancer Epidemiol. Biomark. Prev. 26, 17\u201320 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1603_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.euo.2024.02.003","volume":"7","author":"EJ Saunders","year":"2024","unstructured":"Saunders, E. J. et al. Identification of genes with rare loss of function variants associated with aggressive prostate cancer and survival. Eur. Urol. Oncol. 7, 248\u2013257 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1603_CR35","doi-asserted-by":"crossref","unstructured":"Goss, L. B. et al. Polygenic risk score and upgrading in patients with prostate cancer receiving active surveillance. JAMA Oncol. (2024).","DOI":"10.1001\/jamaoncol.2024.5398"},{"key":"1603_CR36","doi-asserted-by":"publisher","first-page":"c4521","DOI":"10.1136\/bmj.c4521","volume":"341","author":"AJ Vickers","year":"2010","unstructured":"Vickers, A. J. et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341, c4521 (2010).","journal-title":"BMJ"},{"key":"1603_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00280-w","volume":"6","author":"AJ Vickers","year":"2022","unstructured":"Vickers, A. J., Sud, A., Bernstein, J. & Houlston, R. Polygenic risk scores to stratify cancer screening should predict mortality not incidence. NPJ Precis Oncol. 6, 32 (2022).","journal-title":"NPJ Precis Oncol."},{"key":"1603_CR38","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1038\/s41588-025-02342-8","volume":"57","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Limited overlap between genetic effects on disease susceptibility and disease survival. Nat. Genet. 57, 2418\u20132426 (2025).","journal-title":"Nat. Genet."},{"key":"1603_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1940-6207.CAPR-10-0292","volume":"4","author":"MM Pomerantz","year":"2011","unstructured":"Pomerantz, M. M. et al. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev. Res (Philos.) 4, 719\u2013728 (2011).","journal-title":"Cancer Prev. Res (Philos.)"},{"key":"1603_CR40","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ng1808","volume":"38","author":"LT Amundadottir","year":"2006","unstructured":"Amundadottir, L. T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652\u2013658 (2006).","journal-title":"Nat. Genet."},{"key":"1603_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01097-2","volume":"16","author":"C Meijuan","year":"2023","unstructured":"Meijuan, C., Meng, X., Fang, L. & Qian, W. Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments. J. Ovarian Res. 16, 16 (2023).","journal-title":"J. Ovarian Res"},{"key":"1603_CR42","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","volume":"9","author":"BF Darst","year":"2023","unstructured":"Darst, B. F. et al. Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer. JAMA Oncol. 9, 1514\u20131524 (2023).","journal-title":"JAMA Oncol."},{"key":"1603_CR43","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1002\/ijc.31746","volume":"143","author":"E Kaikkonen","year":"2018","unstructured":"Kaikkonen, E. et al. ANO7 is associated with aggressive prostate cancer. Int J. Cancer 143, 2479\u20132487 (2018).","journal-title":"Int J. Cancer"},{"key":"1603_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115627","volume":"213","author":"A Hjazi","year":"2023","unstructured":"Hjazi, A. et al. CDKN2B-AS1 as a novel therapeutic target in cancer: mechanism and clinical perspective. Biochem Pharm. 213, 115627 (2023).","journal-title":"Biochem Pharm."},{"key":"1603_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70264","volume":"28","author":"MC Tung","year":"2024","unstructured":"Tung, M. C. et al. Associations of the expression levels and risk variants of CDKN2B-AS1 long noncoding RNA with the susceptibility and progression of prostate cancer. J. Cell Mol. Med. 28, e70264 (2024).","journal-title":"J. Cell Mol. Med."},{"key":"1603_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70871","volume":"14","author":"T Stocks","year":"2025","unstructured":"Stocks, T., H\u00e4ggstr\u00f6m, C. & Fritz, J. Collider bias is an insufficient explanation for the inverse obesity paradox in prostate cancer. Cancer Med. 14, e70871 (2025).","journal-title":"Cancer Med."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01603-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:02:48Z","timestamp":1777050168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01603-9","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.P. reports research grants\/funding from Janssen. L.A.M. reports equity interest in Convergent Therapeutics, unrelated to this work. A.S.K. reports honoraria from Profound, Pfizer, Janssen, and Merck; has served as a consultant for Bristol Myers Squibb and Candel. A.B. is employed by Regeneron Genetics Center. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}